Lonza: Positive start to 2018, driven by expanding healthcare businesses

04 May 2018 --- Lonza has reported a “positive” start to 2018 led by the businesses along the healthcare continuum. The former Capsugel business, now part of Lonza Pharma & Biotech and Lonza Consumer Health, has shown a strong performance following good progress on business and functional integration, the company reports, without giving any details on financial figures. For the coming months, Lonza has announced plans to expand facilities in the US.

Nexira enters strategic partnership for nutritionals, not giving up its acquisition plans

02 May 2018 --- Nexira, a global leader in natural and organic ingredients for the food, health and nutrition industries, has announced a strategic partnership agreement with Omega Pharma NV, one of the largest OTC healthcare companies in Europe and Inqpharm Group (a Zaluvida company), a specialty pharmaceutical company.

Clinical merger: Novartis acquires AveXis for US$8.7bn, expands in gene therapy

09 Apr 2018 --- Novartis has entered into an agreement and plan of merger with AveXis, Inc. to acquire the US-based Nasdaq-listed clinical-stage gene therapy company for US$8.7 billion in cash (US$218 per share). The transaction was unanimously approved by the Boards of both companies. The move comes just days after Novartis agreed to sell its stake in a consumer healthcare joint venture for $13 billion to GlaxoSmithKline.

Health claim victory: EFSA confirms physical performance benefits of carbohydrate solutions

14 Mar 2018 --- The European Food Safety Authority (EFSA) has published a scientific assessment confirming the beneficial health effects of glycemic carbohydrates on the improvement of physical performance during high-intensity and long-lasting physical exercise. As a result, sports nutrition companies will be able to include on-pack claims regarding the performance boosting capacity of products containing carbohydrate solutions (CHO). 

Ancient becomes modern: US$103 million investment for bone broth innovator

12 Mar 2018 --- Ancient Nutrition, a bone broth protein and collagen supplement maker, has secured $103 million in funding through strategic minority investment led by VMG Partners. The company, which is the breakthrough pioneer in Bone Broth Protein supplementation that delivers the benefits of “homemade bone broth in a convenient, easy-to-mix form,” revealed a minority investment from VMG Partners, Hillhouse Capital, ICONIQ Capital, and over 100 members of a co-investor network.

Gelita develops controlled soft gelatin capsule fill release

12 Mar 2018 --- Gelita is offering manufacturers of soft gelatin capsules the opportunity to see first hand the complete spectrum of capsule fill release profiles – including the latest addition to Gelita’s pharmaceutical gelatin portfolio: Gelita EC for enteric performance.

US FDA Nutrition Facts label guidance prompts calls for earlier implementation date

02 Mar 2018 --- The commissioner of the US Food and Drug Administration (FDA), Dr. Scott Gottlieb, has issued new guidance on the proposed Nutrition Facts label to help food manufacturers to make the necessary changes by the upcoming compliance dates. In addition, Gottlieb unveiled plans to launch “a major educational campaign for consumers” regarding the revised labels. However, the Center of Science in the Public Interest (CSPI) has noted that with the guidance, an earlier compliance date for all companies for the updated Nutrition Facts label is both “realistic and achievable.”

Non-compliant supplements: Majority of online retailers fall foul of EU regulations

26 Feb 2018 --- A majority of online traders recently surveyed by the European Commission are offering novel foods and food supplements that clearly do not comply with EU regulations. This is according to the results of the first coordinated official controls of Internet marketed foods carried out by 25 EU Member States, Switzerland and Norway. Nearly 1,100 websites were checked for certain products which are non-compliant with EU food legislation. More specifically, the investigation mainly focused on four non-authorized novel foods and food supplements bearing medicinal claims, namely Agmatine (4 aminobutyl) guanidine sulfate, Acacia rigidula, Epimedium grandiflorum and Hoodia gordonii. 

Natures Crops, De Wit Speciality Oils enter into European distribution partnership for Ahiflower oil

15 Feb 2018 --- Natures Crops International and De Wit Speciality Oils have entered into a distribution agreement for Ahiflower oil in the European dietary supplement marketplace. This alliance is thought to add strategic value for both companies through each company’s leading position in manufacturing and marketing nutraceutical products.

Consumer health care: Nestle loses interest in Merck's OTC unit 

05 Feb 2018 --- Nestle has pulled out of the bid for Merck’s consumer health unit, leaving the race to buy the maker of Seven Seas vitamins and various other nutritional supplements without its main contender, Reuters reports. The news came a week after Johnson & Johnson withdrew from the race to buy US drugmaker Pfizer’s consumer health business, leaving Nestlé, GlaxoSmithKline and Reckitt Benckiser among the potential bidders. 

Fermentation focus: Naturex and Cura sign distribution agreement for koji fermented minerals

31 Jan 2018 --- Naturex has signed a global distribution agreement via its Open Innovation program (Ingenium) with Ames-based Cura for their Koji Minerals line of fermented minerals for the dietary supplement and functional food markets. This year’s launches based on Koji fermentation are a stand-alone iron with optimal bioavailability and slow release effect (results supported by two clinical studies) and a blend of seven minerals (iron, zinc, copper, manganese, selenium, molybdenum, chromium) particularly suitable for the multi minerals segment, Naturex reports.

Nestlé and GSK among potential bidders for Pfizer's consumer health unit, after J&J pulls out of race

29 Jan 2018 --- Johnson & Johnson has withdrawn from the race to buy US drugmaker Pfizer’s consumer health business, leaving Nestlé, GlaxoSmithKline and Reckitt Benckiser among the potential bidders, according to Reuters. Pfizer wants to sell the business, which makes Advil painkillers, Centrum multivitamins and Chapstick lip balm, for no less than US$20 billion, sources have told Reuters. The deadline to submit non-binding offers for the unit is on Thursday.

Probi signs agreement with “global FMCG company” on gut health launch, enjoys Asia-Pacific growth

26 Jan 2018 --- Probi is seeking to further expand into the functional food space with a newly signed agreement with an as-of-yet unnamed global FMCG company. The partnership relates to the launch of a product containing Probi’s bacteria for gut health in North America. In its year-end report, Probi [which is majority owned by Symrise] notes that a launch in the North American market is planned for the second half of 2019, potentially followed by launches in other territories. The agreement is expected to have a significant impact on future sales and earnings in Probi’s Functional Food business area. 

Frutarom takes full ownership of Enzymotec, sells krill oil business to Aker BioMarine

19 Jan 2018 --- Frutarom Industries has completed its acquisition of full ownership of Enzymotec. Upon completion of the transaction on January 11, 2018, Enzymotec shares were delisted from trading on NASDAQ and it ceased to be a public company. Frutarom reports that it is working towards implementing the full merger plan of all Enzymotec activities through the rapid, efficient and comprehensive integration of both companies’ activities in the areas of management, R&D, sales and marketing, production and supply chain. As part of its merger plan, Frutarom has announced the sale of Enzymotec’s krill oil business to Aker BioMarine.

EFSA rejects Unilever black tea health claim

18 Jan 2018 --- The European Food and Safety Authority (EFSA) has rejected a health claim regarding black tea’s effects on the maintenance of normal endothelium-dependent vasodilation in adults. The application, submitted for authorization of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by Unilever, pertained to “black tea beverages, either freshly prepared or reconstituted from water extract powders of black tea, characterized by the content of flavanols (expressed as catechins plus theaflavins) of at least 30 mg per 200 ml serving.” 

New supermarket in food desert may trigger economic and health gains, US study finds

20 Dec 2017 --- Opening a new supermarket in a low-income neighborhood may improve residents' economic well-being and health, even if residents don't necessarily buy healthier food from the store, according to a new RAND Corporation study. The researchers studied a low-income neighborhood in Pittsburgh, Pennsylvania, where a new supermarket opened after decades of absence, and found that residents reported improvements across a number of economic and health benchmarks a year after the store opened, as compared to residents of a similar neighborhood that did not have a supermarket.

Nutrition industry “feels positive” about new EU rules for novel foods: survey

19 Dec 2017 --- According to research by the organizers of Vitafoods Europe, many people working in the nutrition industry feel positive about the EU’s new process for the approval of novel foods. However, experts are warning that there could be adverse implications for some companies’ intellectual property portfolios. The new regulations on novel foods, defined as anything without a significant history of consumption in the EU before 15 May 1997, come into force on 1 January 2018. For the first time, the approval system will be centralized, with applications submitted to the European Commission rather than individual member states.

Frutarom finalizes AB-Fortis micro-encapsulation technology acquisition

13 Dec 2017 --- Frutarom has acquired AB-Fortis activities, including a patent-protected micro-encapsulation technology that enables delivery of iron with increased biological absorption. Frutarom announced the signing of an agreement with AB-Biotics S.A. of Spain for the acquisition of the activity of AB-Fortis in November.

Kappa Bioscience moves to expand vitamin K2 presence in US with new appointments

13 Dec 2017 --- Kappa Bioscience AS, maker of K2Vital vitamin K2 MK-7, has appointed Garnet Pigden and New Jersey-based D2C to head-up the continued development of Kappa’s position in the US market. The appointment spans the establishment of strategy, infrastructure, partnerships and key accounts in support of an overall objective of solidifying vitamin K2 in mainstream US markets and channels, according to Kappa.

Enzymotec and Frutarom merger gets shareholder green light

12 Dec 2017 --- The shareholders of Israeli specialty chemicals company Enzymotec Ltd. have approved by large majority the merger transaction between Frutarom and Enzymotec. The transaction was approved at Enzymotec’s General Meeting by 99.9 percent majority of shareholders present at the meeting and entitled to vote, Frutarom Industries Ltd. reports.

loading